Macular Degeneration Clinical Trial
Official title:
Improving Vision in Adults With Macular Degeneration, Study 2: The Effect of Concurrent Perceptual Learning and Brain Stimulation
The purpose of this study is to test whether a kind of brain stimulation called anodal transcranial direct current stimulation (a-tDCS) can be combined with perceptual learning to improve the ability of people with age-related macular degeneration (AMD) or juvenile macular degeneration (JMD) to read words presented to them on a computer screen better than if perceptual learning alone were used. In addition, secondary measures of visual acuity will also be examined to determine whether brain stimulation can allow patients to resolve finer details of an image. The proposed treatment is the application of a-tDCS onto the participant's head, with brain stimulation aimed at Primary Visual Cortex toward the occipital pole, while patients undergo six separate sessions of training. The investigators will test the ability of participants to read words before the start of the training sessions (pre test) and after the completion of all training sessions (post test). This is a between-subjects design, and half of the participants will receive true stimulation, and the other half will receive sham stimulation. The difference between the pre and post tests when receiving active stimulation will be compared to the difference when receiving sham stimulation, because the sham stimulation is not expected to influence reading beyond a placebo. The aim of the study is to examine the potential of concurrent brain stimulation and perceptual learning as an effective treatment for macular degeneration that may be used in conjunction with more traditional eye-based interventions. The investigators hypothesize that the brain stimulation will enable higher performance in the reading task after and secondary measures after perceptual training due to an increase in the cortical excitability of the stimulated brain cells.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of AMD (age 60+) or JMD (current age 18+). 2. Visual acuity (VA); between 6/9-6/96 in the better eye 3. Best-corrected near visual acuity of 4.0M at 40 cm or better in the better eye 4. Stable vision in previous 3 months (patient report) 5. Central vision loss Exclusion Criteria: 1. Diagnosed dementia. 2. Not fluent in reading English (Waterloo) or Chinese characters (Hong Kong). 3. Any ocular surgery (including anti-vegF injections) within the duration of the study, except for: A. Chronic and continuous injections for at least 1 year. B. Injections stopped at least 2 months before participation. C. Injections in the untested eye 4. Ocular pathology other than JMD or AMD that can significantly reduce central vision. Example: mild cataract of grade 2 or below is acceptable 5. Severe hearing impairment. 6. Contraindications for brain stimulation |
Country | Name | City | State |
---|---|---|---|
Canada | University of Waterloo | Waterloo | Ontario |
Hong Kong | The Hong Kong Polytechnic University | Hung Hom | Kowloon |
Lead Sponsor | Collaborator |
---|---|
University of Waterloo | The Hong Kong Polytechnic University |
Canada, Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Rapid Serial Visual Presentation (RSVP) Reading performance before and right after training. | Behavioral Measure - Participants will verbally read words presented on a computer. A variety of speeds and sizes will be presented, so that an accurate measure of the maximum reading speed, and the smallest text size readable at the maximum reading speed can be calculated. The maximum reading speed and smallest text size will be measured before and after training. The outcome measures are the change in these reading measurements from pre test to post test. | The pre test and post test will take roughly 1 hour to complete, and they will be roughly 4-7 weeks apart. | |
Primary | Change in Rapid Serial Visual Presentation (RSVP) Reading performance 30 days after training | Behavioral Measure - Participants will verbally read words presented on a computer. A variety of speeds and sizes will be presented, so that an accurate measure of the maximum reading speed, and the smallest text size readable at the maximum reading speed can be calculated. The maximum reading speed and smallest text size will be measured before and after training. The outcome measures are the change in these reading measurements from pre test to the 30 day follow up. | The test will take roughly 1 hour to complete, and they will be roughly 7-10 weeks apart. | |
Secondary | Change in Uncrowded Visual Acuity before and just after training | Visual acuity as measured by participants indicating the orientation of the gap present in a Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to the post test | The pre test and post test will take roughly 5 minutes to complete, and they will be roughly 4-7 weeks apart. | |
Secondary | Change in Uncrowded Visual Acuity before and 30 days after training | Visual acuity as measured by participants indicating the orientation of the gap present in a Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to the 30 day follow up. | The pre test and post test will take roughly 5 minutes to complete, and they will be roughly 7 to 10 weeks apart. | |
Secondary | Change in Crowded Visual Acuity before and just after training | Visual acuity as measured by participants indicating the orientation of the gap present in a Crowded (Ring) Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to post test. | The tests will take roughly 5 minutes to complete, and they will be roughly 4 - 7 weeks apart. | |
Secondary | Change in Crowded Visual Acuity before and 30 days after training | Visual acuity as measured by participants indicating the orientation of the gap present in a Crowded (Ring) Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to the 30 day follow up. | The tests will take roughly 5 minutes to complete, and they will be roughly 7 - 10 weeks apart. | |
Secondary | Change in Contrast Sensitivity before and just after training | Contrast sensitivity as measured by participants indicating the orientation of the gap present in a Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to the post test. | The tests will take roughly 5 minutes to complete, and they will be roughly 4 - 7 weeks apart. | |
Secondary | Change in Contrast Sensitivity before and 30 days after training | Contrast sensitivity as measured by participants indicating the orientation of the gap present in a Landolt C stimulus using the freely available FrACT software https://michaelbach.de/fract/index.html . The outcome measure is the change in performance from pre test to the 30 day follow up. | The tests will take roughly 5 minutes to complete, and they will be roughly 7-10 weeks apart. | |
Secondary | Change in Temporal Visual Span before and just after training | Three unrelated Chinese characters will appear at the centre of a monitor for a range of exposure times. Participants will be asked to recognize all three characters in a correct order. Both horizontal and vertical presentation will be assessed. The outcome measures are the changes in time for recognizing the characters from pre test to the post test. | The test will take roughly 1.5 hours to complete, and they will be roughly 5-8 weeks apart | |
Secondary | Change in Spatial Visual Span before and just after training | Three unrelated Chinese character will appear at different character positions for a fixed exposure time, while participants will be asked to keep fixation at the centre but recognize all three characters in a correct order. Both horizontal and vertical presentation will be assessed. The outcome measures are the changes in the size of the spatial visual span from pre test to the post. | The test will take roughly 1.5 hours to complete, and they will be roughly 5-8 weeks apart. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |